

*This report contains the collective views of an international group of experts and  
does not necessarily represent the decisions or the stated policy of the World Health Organization*

**WHO Technical Report Series**

**878**

---

# **WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION**

---

Forty-seventh Report



---

**World Health Organization**

**Geneva 1998**

WHO Library Cataloguing in Publication Data

WHO Expert Committee on Biological Standardization (1996 : Geneva, Switzerland)  
WHO Expert Committee on Biological Standardization : forty-seventh report.

(WHO technical report series ; 878)

1. Biological products — standards I. Title II. Series

ISBN 92 4 120878 3  
ISSN 0512-3054

(NLM Classification: QW 8Q0)

The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed to the Office of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available.

**© World Health Organization 1998**

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

**Typeset in Hong Kong  
Printed in Spain**

97/11794 — Best-set/Fotojoe — 7500

# Contents

Introduction	1
General	2
Developments in biological standardization	2
Statens Seruminstitut	3
Reviews of the field of biological standardization	3
World Trade Organization	4
WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce	5
Standardization of manufacturer-specific rDNA products or mutant forms of biological products	5
Hyaluronidase and pharmaceutical enzymes	5
Reverse transcriptase activity in avian cells	6
Cytokines	6
Reference preparation for evaluating hepatitis B and C and HIV diagnostic kits	7
Standardization of gene-amplification methods for the viral safety testing of blood and blood products	7
Requirements and guidelines for biological substances	8
Requirements for cell substrates used for production of biologicals	8
Requirements for acellular pertussis vaccines	8
Guidelines for assuring the quality of DNA vaccines	9
Guidelines for peptide vaccines	9
International reference materials	9
Antibiotics	9
Review of reference materials	9
Antibodies	10
Anti-rubella immunoglobulin and anti-rubella serum	10
Anti-thyroid microsome serum	11
Blood products and related substances	11
Blood coagulation factors II, VII, IX and X in plasma	11
Blood coagulation factor IX concentrate	11
Blood coagulation factors II, IX and X concentrate	12
Recombinant ferritin	12
Whole blood folate	13
Thromboplastin, human, recombinant, plain	13
Reference preparations for blood coagulation factor VIII concentrate	14
Cytokines	14
Interleukin-5	14
Interleukin-7	14
Interleukin-9	14
Interleukin-11	15
Interleukin-12	15

Interleukin-13	15
Interleukin-15	15
Leukaemia inhibitory factor	15
Oncostatin M	15
Tumour necrosis factor, beta	16
Nerve growth factor	16
Endocrinological and related substances	16
Thyroid-stimulating hormone, human, recombinant	16
Miscellaneous	17
MAPREC analysis of poliovirus type 3 (Sabin)	17
Endotoxin	17
Annex 1	
Requirements for the use of animal cells as <i>in vitro</i> substrates for the production of biologicals	19
Annex 2	
Guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines	57
Annex 3	
Guidelines for assuring the quality of DNA vaccines	77
Annex 4	
Biological substances: International Standards and Reference Reagents	91
Annex 5	
Requirements for Biological Substances and other sets of recommendations	95

# WHO Expert Committee on Biological Standardization

Geneva, 7–11 October 1996

## Members

- Dr D. Calam, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Rapporteur*)
- Dr S. Drozdov, Director, Institute of Poliomyelitis and Viral Encephalitides, Moscow, Russian Federation
- Dr I.D. Gust, Research and Development Director, CSL Ltd, Parkville, Victoria, Australia
- Dr J.G. Kreeftenberg, Bureau for Quality Assurance and Regulatory Affairs, National Institute for Public Health and Environmental Protection, Netherlands (*Vice-Chairman*)
- Dr F.A. Ofosu, Department of Pathology, McMaster University, Hamilton, Ontario, Canada
- Dr J.C. Petricciani, Vice-President, Genetics Institute, Cambridge, MA, USA (*Chairman*)
- Mr Zhou Hai-jun, Director, National Institute for the Control of Pharmaceutical and Biological Products, Temple of Heaven, Beijing, China

## Representatives of other organizations

- Council of Europe*  
Mr J.-M. Spieser, European Department for the Quality of Medicines, Council of Europe, Strasbourg, France
- International Association of Biological Standardization*  
Professor F. Horaud, Pasteur Institute, Paris, France
- Dr G. Schild, Director, National Institute for Biological Standards and Control, Potters Bar, Herts., England
- International Federation of Pharmaceutical Manufacturers Associations*  
Dr M. Duchêne, Director, Quality Control, SmithKline Beecham Biologicals, Rixensart, Belgium
- Dr B. Montagnon, Head, Regulatory Affairs for Vaccines, Pasteur Mérieux Sera and Vaccines, Marcy l'Etoile, France
- International Society on Thrombosis and Haemostasis*  
Dr A. Tripodi, Haemophilia and Thrombosis Centre, Milan, Italy

## Secretariat

- Dr W.G. van Aken, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands (*Temporary Adviser*)
- Dr F.S. Antezana, Assistant Director-General, World Health Organization, Geneva, Switzerland
- Dr P. Corran, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr V. Grachev, Deputy Director, Institute of Poliomyelitis and Viral Encephalitides,  
Moscow, Russian Federation (*Temporary Adviser*)

Dr E. Griffiths, Chief, Biologicals, World Health Organization, Geneva, Switzerland  
(*Secretary*)

Dr G. Hansen, Statens Seruminstitut, Copenhagen, Denmark (*Temporary Adviser*)

Dr M.C. Hardegree, Director, Office of Vaccine Research and Review, Center for  
Biologics Evaluation and Research, Food and Drug Administration, Rockville,  
MD, USA (*Temporary Adviser*)

Dr K. Haslov, Statens Seruminstitut, Copenhagen, Denmark (*Temporary Adviser*)

Dr J.E. Idänpään-Heikkilä, Director, Division of Drug Management and Policies,  
World Health Organization, Geneva, Switzerland

Dr A.M. Padilla, Scientist, Biologicals, World Health Organization, Geneva,  
Switzerland

Dr J. Robertson, National Institute for Biological Standards and Control, Potters  
Bar, Herts., England (*Temporary Adviser*)

Dr D. Thomas, Witney, Oxford, England (*Temporary Adviser*)

Dr K. Zoon, Director, Center for Biologics Evaluation and Research, Food and Drug  
Administration, Rockville, MD, USA (*Temporary Adviser*)

## Introduction

The WHO Expert Committee on Biological Standardization met in Geneva from 7 to 11 October 1996. The meeting was opened on behalf of the Director-General by Dr F.S. Antezana, Assistant Director-General.

Dr Antezana explained that the shorter meeting that year followed the pattern established for other WHO Expert Committees. As recommended by the Committee in 1995, progress and development reports had been combined into a single agenda item so that attention could be directed to requirements and guidelines, reports of consultations and proposals for establishment and discontinuation of international reference materials.

He emphasized the importance of the work of the Committee to both developed and developing countries and the expansion of the field of biological products and its increasing diversity. Such diversification, together with the development of products derived by new biotechnologies, raised new and significant issues of safety, and he stressed that the challenge was to ensure public safety while not inhibiting the development of potentially important products through inappropriate or restrictive requirements.

Dr Antezana recalled the importance of obtaining international consensus regarding procedures for ensuring the safety and efficacy of new biological products. At the same time, it was necessary to ensure that requirements for existing products reflect scientific and technical advances. The role of well characterized reference materials, internationally established and supplied, was fundamental in contributing to the quality and safety of biological products.

Dr Antezana noted that a review of the scientific basis of the standardization and quality control of biological substances used in human medicine had been conducted recently for the National Biological Standards Board of the United Kingdom, which had responsibility for supervision of one of the WHO International Laboratories for Biological Standards. This review had been undertaken with the collaboration of WHO and the support of the European Medicines Evaluation Agency, the European Pharmacopoeia and the United States Food and Drug Administration. The report was to be presented during the meeting, and its conclusions had international implications that the Committee should consider.

He thanked the WHO International Laboratories for their important contribution to the programme of biological standardization, and

thanked the participants in WHO meetings and collaborative studies for the vital contribution they make to the international reputation and success of the programme.

The death of Dr D.I. Magrath, who served with distinction at WHO as Chief, Biologicals, from 1987 to 1994 was noted with deep regret.

## General

### Developments in biological standardization

The Committee was informed of the continued demand for international reference materials distributed by the International Laboratories for Biological Standards. As proposed by the Committee in 1995, work in progress in the various International Laboratories was summarized. Attention was drawn to a review of reference reagents for blood-typing sera; to a meeting planned for November 1996 to consider issues relating to immunoassays of cytokines; and to the need to review the requirements for antivenoms. In response to comments received concerning the measurement of antibodies, a WHO Informal Consultation would be held to prepare a report for consideration by the Committee in 1997.

The Committee discussed the importance of rapid dissemination of its decisions. National control authorities and manufacturers needed ready access to newly adopted guidelines and requirements, as well as information on the establishment of international reference materials. However, publication of the Committee's report could take longer than was ideal. Partly for these reasons, a summary of the major decisions of the 1995 meeting, including changes in the list of international reference materials, had appeared in the *Weekly epidemiological record*.<sup>1</sup> The Committee nevertheless urged WHO to seek other ways to speed up the dissemination of its decisions.

The Committee was informed of recent data concerning the presence of sequences of simian virus 40 (SV40) in certain human tumour tissues. It was also informed that simian virus 40 had not been present in poliomyelitis vaccine since the early 1960s and that tests to ensure its absence are performed routinely. The Committee requested the Secretariat to monitor developments.

The Committee was also informed that two WHO meetings had been held to discuss the public health implications of transmissible

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30656](https://www.yunbaogao.cn/report/index/report?reportId=5_30656)

